Drug innovators operate in the dark when it comes to real-world patient access. They invest billions each year to support access and uptake. Despite developing transformative therapies, the life sciences industry lacks visibility into the fragmented U.S. payer system, making it nearly impossible to understand — let alone fix — the barriers patients face in getting treated.